Feel free get in touch with us via phone or send us a message.
Economic evaluation and health technology assessments
HEC has vast experience in economic and outcome evaluations for many types of interventions, technologies and products to inform adoption and reimbursement decisions. We can undertake these using modelling approaches that draw on a range of existing data, or through new research, trials and observational studies.
An economic evaluation starts with an accurate structure of the current treatment pathways or protocol, and defining proposed changes to this, to then appropriately discern potential implications for outcomes and costs. We have expertise in detailed and specialist health costing, as well as various methods to measure and value outcomes, both in monetary terms and in terms of patient health and well-being. Where relevant, we can also investigate associated cost structures to provide insights into budgets and how to improve efficiency and productivity. We can help design prospective economic evaluations (e.g. as part of broader clinical trials, including adding economic components to research proposals), or undertake such evaluations using modelling approaches. We pride ourselves in clear and transparent models, working with the best evidence available and other relevant insights, and sensitively, but realistically, exploring the best options. Our models have stood up to scrutiny from many appraisal agencies and academic reviewers. They are also highly usable and interactive, allowing you to explore options and refine the assumptions and inputs as your product or programme is implemented and real-world evidence is generated. Please contact us.
Related Case Studies
The dtb-Instilla catheter is a drug delivery system that delivers a precise dose of medication directly into the bladder. This should improve the effectiveness of UTI (urinary tract infection) treatment. Using the new catheter can also mean fewer hospital visits and fewer antibiotic treatments. We assessed the cost-effectiveness of using the dtb-Instilla catheter for treating episodes of urinary tract infections in patients with bladder cancer and multiple sclerosis using intermittent self-catheterisation.
A probabilistic Markov decision model was developed to assess the cost-effectiveness of using intravesical antibiotic therapy (ITV ATB) versus oral antibiotic therapy (Oral ATB). This model was designed to capture the different health states that adults using intermittent self-catheterisation may experience throughout their lifetime. The cost-effectiveness analysis was carried out from an NHS perspective. Results were expressed in terms of costs, QALYs (Quality Adjusted Life Years), and incremental cost per QALY gained.
The results of the cost-effectiveness analysis indicate that, over a lifetime, the intravesical antibiotic therapy using dtb-Instilla catheter is £25,203 more costly but results in an average gain of 4.032 QALYs per patient compared with oral antibiotic therapy. This yields an ICER (incremental cost-effectiveness ratio) of £6,250 per QALY gain, showing that the ICER for intravesical antibiotic therapy with dtb-Instilla catheter is much lower than recommended threshold values (£20 000 to £30 000) and therefore a very cost-effective option for adopters.